drugset
drugset / Trial / NCT03167541

Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study

NCT03167541 ↗

Phase 1 Completed 18 enrolled Reckitt Benckiser Healthcare (UK) Limited Simbec Research · collab
RandomizedCrossoverOpen-labelOther

Summary

This study is being conducted to investigate the rate and extent of naproxen absorption from the Test naproxen sodium formulation is bioequivalent to Aleve® naproxen sodium, a Reference product currently marketed in The Netherlands in order to support the registration of the Reckitt Benckiser (RB) naproxen sodium (220 mg tablets).

Timeline

Start
2016-10-12
Primary completion
2016-12-02
Completion
2016-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 440 mg —

Indications

No indication recorded.